We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Lonza and Hyglos Reach Agreement for Endotoxin Detection Patents
News

Lonza and Hyglos Reach Agreement for Endotoxin Detection Patents

Lonza and Hyglos Reach Agreement for Endotoxin Detection Patents
News

Lonza and Hyglos Reach Agreement for Endotoxin Detection Patents

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Lonza and Hyglos Reach Agreement for Endotoxin Detection Patents"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Lonza Walkersville, Inc. and Hyglos GmbH have announced that they have reached a mutually beneficial global settlement which includes a license agreement for Hyglos under certain Lonza patents in the area of endotoxin detection.

Specifically, the agreement allows Hyglos to use recombinant factor C technology protected by Lonza’s patents to produce Hyglos’ own endotoxin products.

The agreement also includes the dismissal of the law suit Lonza previously filed against Hyglos.

The terms of the settlement are confidential.

“Thanks to this agreement an important door has opened for a new era in endotoxin detection. We are convinced that Hyglos’ innovative assays, entirely based on recombinant molecules, are addressing important needs of endotoxin testing laboratories worldwide” said Dr. Wolfgang Mutter, General Manager of Hyglos GmbH.

“We are very glad to have reached this agreement with Hyglos. Endotoxin detection using recombinant factor C instead of Limulus amoebocyte lysates has recently been acknowledged by the FDA as an alternative method. We believe that this sustainable animal-free alternative will be the future of endotoxin detection.” concluded Dr. Teun Van der Heide, Head Lonza Bioscience.

Advertisement